Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Amortization of Deferred Charges (2022 - 2025)

BioXcel Therapeutics has reported Amortization of Deferred Charges over the past 4 years, most recently at -$3.8 million for Q4 2025.

  • Quarterly results put Amortization of Deferred Charges at -$3.8 million for Q4 2025, down 1803.6% from a year ago — trailing twelve months through Dec 2025 was -$280000.0 (down 159.96% YoY), and the annual figure for FY2025 was $1.7 million, up 253.75%.
  • Amortization of Deferred Charges for Q4 2025 was -$3.8 million at BioXcel Therapeutics, down from $441000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for BTAI hit a ceiling of $2.7 million in Q1 2025 and a floor of -$3.8 million in Q4 2025.
  • Median Amortization of Deferred Charges over the past 4 years was $321000.0 (2022), compared with a mean of $160400.0.
  • Peak annual rise in Amortization of Deferred Charges hit 6104.65% in 2025, while the deepest fall reached 1803.6% in 2025.
  • BioXcel Therapeutics' Amortization of Deferred Charges stood at $457000.0 in 2022, then tumbled by 65.43% to $158000.0 in 2023, then soared by 40.51% to $222000.0 in 2024, then crashed by 1803.6% to -$3.8 million in 2025.
  • The last three reported values for Amortization of Deferred Charges were -$3.8 million (Q4 2025), $441000.0 (Q3 2025), and $393000.0 (Q2 2025) per Business Quant data.